Sanders Morris Harris LLC Trims Stock Position in AbbVie Inc. $ABBV

Sanders Morris Harris LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 90.8% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 1,908 shares of the company’s stock after selling 18,921 shares during the quarter. Sanders Morris Harris LLC’s holdings in AbbVie were worth $480,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ABBV. Ranch Capital Advisors Inc. raised its stake in shares of AbbVie by 37.0% in the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after buying an additional 4,017 shares during the period. Calamos Advisors LLC grew its stake in shares of AbbVie by 3.4% during the 4th quarter. Calamos Advisors LLC now owns 466,290 shares of the company’s stock valued at $106,543,000 after acquiring an additional 15,458 shares during the period. Bingham Private Wealth LLC purchased a new stake in AbbVie in the 4th quarter worth approximately $1,147,000. Axecap Investments LLC raised its stake in AbbVie by 713.2% during the 4th quarter. Axecap Investments LLC now owns 16,320 shares of the company’s stock worth $3,729,000 after acquiring an additional 14,313 shares during the period. Finally, Legacy Edge Advisors LLC purchased a new position in AbbVie during the fourth quarter valued at approximately $1,265,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund an acquisition. While the financing increases interest obligations, it provides capital to pursue a transaction intended to strengthen the company’s growth profile. AbbVie prices $9.9B senior notes to fund acquisition
• Positive Sentiment: Analyst sentiment remains favorable. Erste Group upgraded AbbVie from “hold” to “buy,” while Cantor Fitzgerald raised its price target to $285, implying additional upside from recent trading levels. Cantor Fitzgerald boosts AbbVie price target
• Positive Sentiment: Second-quarter results exceeded expectations: revenue increased 10.2% year over year to $16.99 billion, and adjusted EPS of $3.65 surpassed the $3.61 consensus estimate. Growth in immunology and neuroscience helped offset concerns about the post-Humira transition, while third-quarter EPS guidance of $3.84–$3.88 indicates continued earnings momentum. AbbVie Q2 results and outlook
• Positive Sentiment: The FDA accepted Allergan Aesthetics’ supplemental application for BOTOX Cosmetic in masseter muscle prominence, expanding a major product into a potential new aesthetic indication. Approval could broaden BOTOX’s revenue opportunity, although the application still requires regulatory review. FDA accepts BOTOX Cosmetic application
• Positive Sentiment: Canada’s drug agency recommended conditional reimbursement of UBRELVY for acute migraine treatment, potentially improving access and supporting international growth for the newer migraine medicine. UBRELVY reimbursement recommendation
• Neutral Sentiment: RemeGen forecast a significant profit turnaround, citing stronger drug sales and an AbbVie licensing deal. The development supports AbbVie’s partnered pipeline but is unlikely to materially affect near-term results. RemeGen licensing update
• Negative Sentiment: Valuation remains a risk. Commentary noted ABBV’s trailing P/E near 70 and a model estimating fair value roughly $50 below the current level, raising concerns that much of the positive outlook may already be reflected in the stock. AbbVie year-end price prediction

AbbVie Price Performance

ABBV stock opened at $245.98 on Thursday. The business has a 50-day moving average price of $240.90 and a 200 day moving average price of $224.61. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The company has a market capitalization of $434.59 billion, a P/E ratio of 69.49, a PEG ratio of 0.81 and a beta of 0.30.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the firm earned $2.97 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts anticipate that AbbVie Inc. will post 14.06 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of analyst reports. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday. Royal Bank Of Canada upped their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a report on Friday, July 10th. Morgan Stanley reiterated an “overweight” rating and issued a $296.00 price target on shares of AbbVie in a research note on Monday. HSBC reissued a “buy” rating and issued a $300.00 target price on shares of AbbVie in a report on Monday, July 6th. Finally, Cantor Fitzgerald lifted their price objective on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $272.76.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.